Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 14 de 14
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
West Indian Med J ; 63(2): 184-5, 2014 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25303257

RESUMEN

Neisseria meningitidis infection should be considered in patients presenting with septic arthritis especially if Gram-negative diplococcic are observed on Gram-stain.

2.
Aliment Pharmacol Ther ; 14(2): 225-31, 2000 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-10651664

RESUMEN

BACKGROUND: The efficacy of proton pump inhibitor based triple therapy in patients from South-East Asia, where metronidazole resistance is reportedly high, has not been formally assessed in randomized, multicentre trials. AIM: To compare the eradication rates of Helicobacter pylori, ulcer healing rates and side-effects of three regimens of omeprazole triple therapy in patients with duodenal ulcer from South-East Asia and to study the impact of metronidazole resistance. METHODS: A single blind, randomized parallel group, comparative multicentre study. A total of 246 patients from 15 centres in four South-East Asian countries were randomized to receive OAC (omeprazole 20 mg b.d., amoxycillin 1 g b. d., clarithromycin 500 mg b.d.), OAM (omeprazole 20 mg b.d., amoxycillin 1 g b.d., metronidazole 400 mg b.d.) or OMC (omeprazole 20 mg b.d., metronidazole 400 mg b.d., clarithromycin 500 mg b.d.) for 7 days. After triple therapy, the patients were further randomized to receive either omeprazole or placebo for 7 days. Upper gastrointestinal endoscopy was performed before treatment and 4 weeks after treatment. Biopsies for culture and for histopathological examination for H. pylori were taken from corpus and antrum before treatment and 4 weeks after treatment. RESULTS: The eradication rates were intention-to-treat/per protocol (95% CI): OAC 87% (79-94%)/94% (89-100%); OAM 80% (70-89%)/91% (83-98%); OMC 85% (77-93%)/94% (88-100%). The difference in eradication rates between the three groups was not statistically significant (P=0.419). Pre-treatment metronidazole resistance, was found in 34% of isolates and was a significant prognostic factor in patients receiving OAM (odds ratio 5.26) but not in patients receiving OAC or OMC. CONCLUSIONS: All three treatment regimens were safe, well tolerated and highly effective for eradication of H. pylori and ulcer healing. Pre-treatment metronidazole resistance reduced the efficacy of OAM but did not affect the efficacy of OMC.


Asunto(s)
Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Antiulcerosos/uso terapéutico , Úlcera Duodenal/tratamiento farmacológico , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Metronidazol/administración & dosificación , Omeprazol/administración & dosificación , Adolescente , Adulto , Anciano , Amoxicilina/efectos adversos , Amoxicilina/uso terapéutico , Antibacterianos/efectos adversos , Asia Sudoriental , Biopsia , Claritromicina/efectos adversos , Claritromicina/uso terapéutico , Farmacorresistencia Microbiana/fisiología , Quimioterapia Combinada , Endoscopía , Femenino , Helicobacter pylori/efectos de los fármacos , Humanos , Masculino , Metronidazol/efectos adversos , Persona de Mediana Edad , Omeprazol/efectos adversos , Método Simple Ciego
3.
Artículo en Inglés | MEDLINE | ID: mdl-8171292

RESUMEN

There is a need to define Quality of Life and to develop a practical method to measure objectively this aspect in gastrointestinal diseases. This has not been performed in any Asian population. It is proposed that this evaluation be part of future trials in Asia on the basis that Asian patients are culturally, socially and politically different from Westerners.


Asunto(s)
Etnicidad , Calidad de Vida , Asia , Características Culturales , Enfermedades Gastrointestinales/terapia , Humanos
4.
J Gastroenterol Hepatol ; 4 Suppl 2: 53-61, 1989.
Artículo en Inglés | MEDLINE | ID: mdl-2491362

RESUMEN

A double-blind randomized study in 230 Malaysian patients with duodenal ulcer was conducted to compare the proton-pump inhibitor, omeprazole 20 mg, given once daily in the morning, with ranitidine 300 mg, administered once daily at night. After 2 and 4 weeks of treatment, 222 and 220 patients, respectively, were evaluable according to the study protocol. Omeprazole produced significantly higher healing rates than ranitidine at both 2 weeks (75% versus 46%, respectively, P less than 0.0001) and 4 weeks (97% versus 83%, respectively, P = 0.001). Ulcer symptoms were relieved more rapidly by omeprazole than ranitidine. After 2 weeks, daytime epigastric pain was reported by 30% of ranitidine-treated patients but only by 15% of omeprazole-treated patients, which is a statistically significant difference (P = 0.004). No major clinical or biochemical side effects were recorded for either omeprazole or ranitidine. In conclusion, omeprazole 20 mg was found to be superior to ranitidine 300 mg administered once daily for the treatment of duodenal ulcer as measured by ulcer healing and pain relief.


Asunto(s)
Úlcera Duodenal/tratamiento farmacológico , Omeprazol/uso terapéutico , Ranitidina/uso terapéutico , Adulto , Anciano , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad
5.
J Gastroenterol Hepatol ; 4 Suppl 2: 75-81, 1989.
Artículo en Inglés | MEDLINE | ID: mdl-2577478

RESUMEN

Twenty-seven patients with peptic ulcer (19 with duodenal ulcer (DU) and eight with gastric ulcer (GU] refractory to H2-antagonists were treated with 40 mg of omeprazole once daily for 4-8 weeks, depending on the rate of ulcer healing. Clinical assessment, endoscopy and laboratory tests were performed at entry, after 2 and after 4 weeks, and if unhealed, also after 8 weeks' treatment. Ten healed patients were given a maintenance therapy of omeprazole 20 mg daily for up to 12 months during which the patients returned for endoscopy, gastric biopsy and laboratory tests at 3-monthly intervals. The initial treatment healed 15 of 19 (79%) DU patients in 2 weeks and all DU patients by 4 weeks. Seven of eight (87%) GU patients healed in 4 weeks and only one required 8 weeks' treatment. Symptom relief was rapid, with most patients being symptom-free within the first day of treatment. Six patients received 12 months' continuous maintenance therapy, one patient 9 months and three patients 6 months' treatment. All patients remained in remission whilst on omeprazole therapy. No adverse events were reported throughout the study. There were no clinically significant changes in haematology or blood chemistry after healing or during the long-term treatment. Biopsy samples revealed no histological changes in the gastric mucosa at any stage. Omeprazole 40 mg therefore was found to produce rapid healing and symptom relief in Asian patients with H2-antagonist-resistant peptic ulcers. Maintenance therapy with omeprazole 20 mg daily was shown to be safe and effective in preventing recurrence of peptic ulceration.


Asunto(s)
Antagonistas de los Receptores H2 de la Histamina/uso terapéutico , Omeprazol/uso terapéutico , Úlcera Péptica/tratamiento farmacológico , Adulto , Anciano , Evaluación de Medicamentos , Úlcera Duodenal/tratamiento farmacológico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Úlcera Gástrica/tratamiento farmacológico
7.
Med J Aust ; 2(6): 316-7, 1979 Sep 22.
Artículo en Inglés | MEDLINE | ID: mdl-522768

RESUMEN

A patient with diabetes insipidus and hypothyroidism developed anovular menstrual cycles. Ovulation, which was followed by pregnancy, was induced by the administration of clomiphene. In the later stages of pregnancy, an increase in the dosage of vasopressin was necessary to achieve a satisfactory control of the symptoms of diabetes insipidus. Labour was induced before the estimated date of confinement by the intravenous administration of oxytocin and an intra-partum haemorrhage necessitated delivery by the lower-segment caesarean section. The post-partum period was uneventful. Lactation was suppressed on request from the patient.


Asunto(s)
Clomifeno/uso terapéutico , Diabetes Insípida/fisiopatología , Hipotiroidismo/fisiopatología , Infertilidad Femenina/tratamiento farmacológico , Ovulación/efectos de los fármacos , Embarazo en Diabéticas/fisiopatología , Adulto , Anovulación/tratamiento farmacológico , Diabetes Insípida/tratamiento farmacológico , Femenino , Humanos , Trabajo de Parto Inducido , Embarazo , Complicaciones del Embarazo/fisiopatología , Vasopresinas/administración & dosificación
12.
Med J Malaysia ; 33(3): 266-8, 1979 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-522733
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA